TriangleNCT02187783 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline up to approximately 36 months
What was measured
Number of participants Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause.
Groups in this outcome
Ribociclib 600 mg
LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.
| Group | Source count |
|---|---|
| Ribociclib 600 mg | 106 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ribociclib 600 mg | 7.7 | Not reported | 5.3 | 9.2 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.3
- upper Limit
- 9.2
- value
- 7.7
- denoms
- counts
- group Id
- OG000
- value
- 106
- units
- Participants
- description
- Number of participants Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.
- id
- OG000
- title
- Ribociclib 600 mg
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Baseline up to approximately 36 months
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice